

Table S1 Risk of bias assessment with MINORS score

Study	Total	1*	2*	3*	4*	5*	6*	7*	8*	9*	10*	11*	12*
Forde <i>et al.</i> , 2018	21	2	2	2	2	2	2	2	0	2	2	1	2
Gao <i>et al.</i> , 2020	21	2	2	2	2	2	2	2	0	2	2	1	2
Reuss <i>et al.</i> , 2020	21	2	2	2	2	2	2	2	0	2	2	1	2
Eichhorn <i>et al.</i> , 2021	21	2	2	2	2	2	2	2	0	2	2	1	2
Boch <i>et al.</i> , 2022	18	2	2	0	2	2	0	1	2	2	2	1	2
Duan <i>et al.</i> , 2021	21	2	2	2	2	2	2	2	0	2	2	1	2
Sun <i>et al.</i> , 2023	21	2	2	2	2	2	2	2	0	2	2	1	2
Shu <i>et al.</i> , 2020	21	2	2	2	2	2	2	2	0	2	2	1	2
Provencio <i>et al.</i> , 2020	21	2	2	2	2	2	2	2	0	2	2	1	2
Tfayli <i>et al.</i> , 2020	21	2	2	2	2	2	2	2	0	2	2	1	2
Chen <i>et al.</i> , 2022	17	2	2	1	2	2	0	1	0	2	2	1	2
Shen <i>et al.</i> , 2021	21	2	2	2	2	2	2	2	0	2	2	1	2
Zhao <i>et al.</i> , 2021	21	2	2	2	2	2	2	2	0	2	2	1	2
Wu <i>et al.</i> , 2022	17	2	2	1	2	2	0	1	0	2	2	1	2
Chen <i>et al.</i> , 2021	17	2	2	1	2	2	0	1	0	2	2	1	2
Ali <i>et al.</i> , 2023	17	2	2	1	2	2	0	1	0	2	2	1	2
Hou <i>et al.</i> , 2023	17	2	2	1	2	2	0	1	0	2	2	1	2
Zhao <i>et al.</i> , 2023	17	2	2	1	2	2	0	1	0	2	2	1	2
Feng <i>et al.</i> , 2022	17	2	2	1	2	2	0	1	0	2	2	1	2
Xu <i>et al.</i> , 2022	17	2	2	1	2	2	0	1	0	2	2	1	2
Zhu <i>et al.</i> , 2022	17	2	2	1	2	2	0	1	0	2	2	1	2

1*, a stated aim of the study; 2*, inclusion of consecutive patients; 3*, prospective collection of data; 4*, endpoints appropriate to study aim; 5*, unbiased assessment of study endpoint; 6*, follow-up period appropriate to the major endpoint; 7*, less than 5% lost to follow-up; 8*, adequate control group; 9*, contemporary groups; 10*, baseline equivalence of groups; 11*, prospective calculation of study size; 12*, adequate statistical analyses.




Figure S1 Funnel plot. (A) McPR of SCC, (B) MPR of SCC, (C) cPR of SCC, (D) CR of SCC, (E) PR of SCC, (F) SD of SCC, (G) PD of SCC, (H) ORR of SCC, (I) DCR of SCC, (J) McPR of ADC, (K) MPR of ADC, (L) cPR of ADC, (M) CR of ADC, (N) PR of ADC, (O) SD of ADC, (P) PD of ADC, (Q) ORR of ADC, (R) DCR of ADC. McPR, the sum of major pathological response and complete pathological response; SCC, squamous cell carcinoma; MPR, major pathological response; cPR, complete pathological response; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; ADC, adenocarcinoma.

Table S2 The result of Egger's test

Outcome measures	Histological subtypes	P value
McPR	SCC	0.27
	ADC	0.94
MPR	SCC	0.30
	ADC	0.20
cPR	SCC	0.62
	ADC	0.85
CR	SCC	0.94
	ADC	0.41
PR	SCC	0.78
	ADC	0.60
SD	SCC	0.72
	ADC	0.70
PD	SCC	0.41
	ADC	0.45
ORR	SCC	0.81
	ADC	0.65
DCR	SCC	0.61
	ADC	0.47

McPR, the sum of major pathological response and complete pathological response; SCC, squamous cell carcinoma; ADC, adenocarcinoma; MPR, major pathological response; cPR, complete pathological response; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.